-
New Concept Energy, Inc. (NYSE: GBR) shares jumped
88.3 percent to $3.05.
-
Cellect Biotechnology Ltd. (NASDAQ: APOP) shares
climbed 78.6 percent to $11.19 after the company disclosed that the first stem cell transplant has been completed in its Phase
I/II trial.
-
Systemax Inc. (NYSE: SYX) shares rose 27.1 percent
to $9.15 as the company agreed to sell all of its unprofitable European Technology Products Group businesses.
-
Impax Laboratories Inc (NASDAQ: IPXL) surged 22.4
percent to $11.32. Impax named Paul Bisaro as CEO.
-
Regulus Therapeutics Inc (NASDAQ: RGLS) shares
rose 14.3 percent to $1.60.
-
HTG Molecular Diagnostics Inc (NASDAQ: HTGM)
shares gained 12.2 percent to $10.83 after jumping 145.55 percent on Friday.
-
ITUS Corp (NASDAQ: ITUS) shares jumped 11 percent
to $2.69.
-
Weatherford International Plc (NYSE: WFT) surged
10.3 percent to $6.49. Weatherford and Schlumberger (NYSE: SLB) announced plans to form OneStim joint venture. Wells Fargo upgraded
Weatherford International to Outperform.
-
Sears Holdings Corp (NASDAQ: SHLD) shares climbed
10.2 percent to $9.37.
-
Paratek Pharmaceuticals Inc (NASDAQ: PRTK) shares
gained 8.8 percent to $17.25. Allergan and Paratek announced that Phase 3 trials for the treatment of moderate to severe acne
has met primary endpoints.
-
EXACT Sciences Corporation (NASDAQ: EXAS) surged
7.7 percent to $22.70. Cowen & Co. initiated coverage on EXACT Sciences with an Outperform rating.
-
Thermon Group Holdings Inc (NYSE: THR) rose 7.1
percent to $20.73. BMO Capital upgraded Thermon Group to Outperform.
-
HCA Holdings Inc (NYSE: HCA) shares rose 5.1 percent
to $90.42. Mizuho upgraded HCA from Neutral to Buy.
-
Snap Inc (NYSE: SNAP) rose 4.5 percent to $23.76.
Credit Suisse initiated coverage on Snap with an Outperform rating, while Cowen & Co. initiates coverage on the stock with an
Outperform rating. Morgan Stanley initiated Snap with Overweight, while Goldman Sachs initiated Snap with Buy.
-
Dominion Diamond Corp (NYSE: DDC) gained 3.7 percent
to $13.19 as the company announced plans to explore strategic alternatives.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.